Sign in

CIK 0001737953 · Non-accelerated filer<br>Smaller reporting company

Replimune Group, Inc.

Sign in to watch
Ticker
REPL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Mar 31
Incorporated
DE
Entity type
operating
EIN
822082553
Phone
(781) 222-9600
Business address
500 UNICORN PARK, WOBURN, MA, 01801
  1. 3 Insider Initial Statement of Ownership
  2. 4 Derivatives Options or other derivatives
  3. 3 Insider Initial Statement of Ownership
  4. 4 Planned sale Chief Executive Officer sold 10,000 shares at $12.42 ($124,200)
  5. 4 Open-market sale Chief Medical Officer sold 7,246 shares at $10.78 ($78,112)
  6. 4 Open-market sale Chief Commercial Officer sold 5,207 shares at $10.78 ($56,131)
  7. 4 Derivatives Options or other derivatives
  8. 3 Insider Initial Statement of Ownership
  9. 4 Gift Executive Chairman gave 50,000 shares (gift)
  10. 4 Open-market sale Chief Financial Officer sold 8,938 shares at $10.18 ($90,989)
  11. 4 Planned sale Chief Medical Officer sold 15,881 shares at $7.50 ($119,108)
  12. 4 Open-market sale Chief Commercial Officer sold 2,218 shares at $6.47 ($14,350)
  13. 4 Open-market sale Chief Accounting Officer sold 2,298 shares at $6.47 ($14,868)
  14. 4 Open-market sale Chief Operating Officer sold 17,615 shares at $6.47 ($113,969)
  15. 4 Open-market sale Executive Chairman sold 37,928 shares at $6.47 ($245,394)
  16. 4 Open-market sale Director sold 11,464 shares at $6.47 ($74,172)
  17. 4 Open-market sale Chief Executive Officer sold 20,194 shares at $6.47 ($130,655)
  18. 4 Open-market sale Chief Medical Officer sold 6,367 shares at $6.47 ($41,194)
  19. 4 Derivatives Options or other derivatives
  20. 4 Grant or award Chief Executive Officer acquired 83,335 shares (grant or award)

Page 4 of 16 · 316 filings